Improving anticancer activity towards colon cancer cells with a new p53-activating agent.

Liliana RaimundoMargarida EspadinhaJoana SoaresJoana B LoureiroMarco G AlvesMaria M M SantosLucília Saraiva

Published in: British journal of pharmacology (2018)

SYNAP revealed encouraging anticancer activity, either alone or in combination with known chemotherapeutic agents, in colon cancer cells. Apart from its promising application in cancer therapy, SYNAP may provide a starting point for improved p53 activators.

Keyphrases

cancer therapy
drug delivery
signaling pathway
single cell